Medtronic (NYSE:MDT) said today that the FDA approved its InterStim smart programmer, designed to work with the company’s InterStim sacral neurmodulation system intended for tor treating overactive bladder, chronic fecal incontinence and non-obstructive urinary retention. The newly cleared smart programmer is run on a Samsung Electronics (LON:BC94) mobile device and allows clinicians to personalize patient care and manage […]
Samsung’s NeuroLogica, MaxQ AI ink collab distro deal
Samsung Electronics (LON:BC94) subsidiary NeuroLogica said today that it inked a distribution deal with MaxQ AI to integrate its artificial intelligence software with NeuroLogica’s medical imaging tech in the U.S. and EU’s acute care marketplace. Through the deal, NeuroLogica said that it will offer MaxQ’s Accipio IX, part of the AI-company’s FDA-cleared and CE Mark approved […]
Samsung’s NeuroLogica wins $250m US DoD radiology supply contract
Samsung Electronics (LON:BC94) subsidiary NeuroLogica won a $250 million maximum firm-fixed-price contract to supply the US Dept. of Defense with radiology systems, accessories and training, according to a newly posted release. The contract for the Danvers, Mass.-based subsidiary is located in Massachusetts and has a five-year base and an additional five-year option period, according to the […]
HRS 2018 Roundup: Device-related blood clots with Boston Scientific’s Watchman implant
Data from a study of device-related blood clots and the Watchman cardiac implant made by Boston Scientific (NYSE:BSX), presented today at the annual meeting of the Heart Rhythm Society in Boston, indicate the need for aggressive management of patients at risk for device-related thrombosis. There were 74 incidences of DRT in 65 of the 1,739 Watchman […]
FDA taps Apple, J&J and others for health software pre-cert pilot
The FDA yesterday named the nine companies that will be included in a pilot program to pre-certify healthcare software developers. The program was designed with the hopes of reducing the amount of information the regulatory watchdog requires for review. The companies include Apple (NSDQ:AAPL), Fitbit (NYSE:FIT), Johnson & Johnson (NYSE:JNJ), Pear Therapeutics, Phosphorus, Roche (OTC:RHHBY), Samsung, Tidepool and Verily. […]
